ÁAÁlvaro Gimeno Díaz de Atauri

Álvaro Gimeno Díaz de Atauri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Álvaro Gimeno Díaz de Atauri has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lectura crítica (I): Fundamentos, herramientas y su aplicación en artículos científicos sobre pronóstico y efectos perjudiciales

    by Javier González de Dios, María Salomé Albi Rodríguez, Álvaro Gimeno Díaz de Atauri, Laura Cabrera Morente, Elena Pérez González, Carlos Ochoa Sangrador, Pilar Aiuzpurúa Galdeano, María Aparicio Rodrigo, Nieves Balado Insunza, Albert Balaguer Santamaría, et al.


  • Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain

    by María Nieto‐Cid, Teresa Garriga‐Baraut, Ana Mª. Plaza‐Martín, Miguel Tortajada‐Girbés, Javier Torres‐Borrego, Jaime Lozano‐Blasco, Laura Moreno‐Galarraga, Mª. del Mar Folqué‐Giménez, Montse Bosque‐García, Mirella Gaboli, et al.

    Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.Conclusion: The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.


  • Incidence and Prevalence of Children's Diffuse Lung Disease in Spain

    by Alba Torrent-Vernetta, Mirella Gaboli, Silvia Castillo-Corullón, Pedro Mondéjar-López, Verónica Sanz Santiago, Jordi Costa-Colomer, Borja Osona, Javier Torres-Borrego, Olga de la Serna-Blázquez, Sara Bellón Alonso, et al.


  • Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

    by Antonio Nieto García, Teresa Garriga-Baraut, Ana Mª Plaza Martín, María Nieto Cid, Javier Torres Borrego, María Del Mar Folqué Giménez, Jaime Lozano Blasco, Montse Bosque García, Laura Moreno-Galarraga, Miguel Tortajada-Girbés, et al.

    Background: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real‐life cohort reported to date.Methods: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow‐up. The primary outcome was the evolution of the annual number of moderate‐to‐severe exacerbations compared with the baseline period.Results: Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution.Conclusion: In this large, long‐term, observational study, moderate‐to‐severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long‐term treatment in pediatric patients with severe persistent allergic asthma.